Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®

Inclusion Criteria: * Patients with a second degree burn covering 5% to 20% BSA. TBSA covered with burn is allowed to be up to 25%, allowing a maximum of 10% to be third degree burn (only the Second degree burn should be treated) * Burn of thermal origin * Both gender with an age ≥ 5 years at randomization * Signed informed consent * Subjects who are younger than the legal consenting age must have a legally authorized representative Exclusion Criteria: * \- Burns equal to or older than 36 hours * Burns of chemical and electrical origin * Clinically infected Burn (as judged by the investigator) * Treatment of the burn with an active agent before study entry, SSD is allowed up to 24 hours prior to randomization * Patients with necrotising leucocytic vasculitis or pyoderma gangrenosa. * Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer and severe anaemia) judged by the investigator to be a potential interference in the treatment. * Patients with insulin dependent diabetes mellitus * Patients treated with systemic glucocorticosteroids, except patients taking occasional doses or doses less than 10mg prednisolon/day or equivalent. * Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days. * Known allergy/hypersensitivity to any of the components of the investigation products. * Patients with physical and/or mental conditions that are not expected to comply with the investigation. * Participation in other clinical investigation(s) within 1 month prior to start of the investigation * Pregnancy * Previously randomised to this investigation